MUC1

Glycotope Announces Poster Presentations at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Retrieved on: 
Friday, April 30, 2021
Branches of biology, Clinical medicine, Medicine, Lung cancer, Epidermal growth factor receptor, Oncogenes, MUC1, Non-small-cell lung carcinoma, Immunotherapy, Gatipotuzumab

Based on compelling preclinical evidence suggesting a complex interaction between EGFR and TA-MUC1 expressed on the tumor cell surface in driving carcinogenesis, this study assessed the tolerability, safety and preliminary activity of targeting EGFR and TA-MUC1 with glyco-engineered antibodies.

Key Points: 
  • Based on compelling preclinical evidence suggesting a complex interaction between EGFR and TA-MUC1 expressed on the tumor cell surface in driving carcinogenesis, this study assessed the tolerability, safety and preliminary activity of targeting EGFR and TA-MUC1 with glyco-engineered antibodies.
  • Encouraging anti-tumor activity was observed in heavily pretreated CRC and NSCLC patients.
  • GlycoBodies bind to targets (GlycoTargets) tumor-specific carbohydrate structure dependent, enabling the development of highly-specific immunotherapies across a broad range of cancer indications.
  • Currently six clinical and pre-clinical programs based on the GlycoBody technology are under development by Glycotope or its licensing partners.

Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1

Retrieved on: 
Thursday, December 17, 2020
Clinical medicine, Medical specialties, Medicine, Cancer immunotherapy, Virotherapy, MUC1, Immunotherapy, Pankomab, Immunology

Berlin, Germany, December 17, 2020 - Glycotope GmbH, an oncology/immuno-oncology platform company built on world-leading glycobiology expertise, today announces that is has signed an agreement to license a humanized, tumor-specific antibody (GlycoBody) targeting an aberrantly glycosylated tumor associated form of MUC1 (TA-MUC1) to ONK Therapeutics Ltd. (ONK), an innovative natural killer (NK) cell therapy company.

Key Points: 
  • Berlin, Germany, December 17, 2020 - Glycotope GmbH, an oncology/immuno-oncology platform company built on world-leading glycobiology expertise, today announces that is has signed an agreement to license a humanized, tumor-specific antibody (GlycoBody) targeting an aberrantly glycosylated tumor associated form of MUC1 (TA-MUC1) to ONK Therapeutics Ltd. (ONK), an innovative natural killer (NK) cell therapy company.
  • The GlycoBody will be integrated into ONKs pre-clinical program ONKT103, for solid tumors.
  • The expression of these antigens is restricted to cancer cells and by targeting them ONK hopes to increase tumor-specificity and reduce the potential for on-target off-tumor toxicity.
  • This represents further validation of our platforms ability to enable the development of highly-specific immunotherapies across a broad range of cancer indications.

Minerva Biotechnologies Announces License Agreement with Memorial Sloan Kettering Cancer Center for 1XX Technology

Retrieved on: 
Monday, June 22, 2020
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Medicine, MSK, MUC1, Memorial Sloan Kettering Cancer Center, Clinical medicine, Health, Immunotherapy

Minerva Biotechnologies (Minerva) today announced that it has licensed from Memorial Sloan Kettering Cancer Center (MSK) 1XX technology for use with Minervas proprietary anti-MUC1* antibodies to increase CAR T cell persistence in patients.

Key Points: 
  • Minerva Biotechnologies (Minerva) today announced that it has licensed from Memorial Sloan Kettering Cancer Center (MSK) 1XX technology for use with Minervas proprietary anti-MUC1* antibodies to increase CAR T cell persistence in patients.
  • Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering at MSK and inventor of the 1XX technology said, We are excited by the prospect of targeting MUC1* with MSKs 1XX CAR technology.
  • Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer and cellular therapies in regenerative medicine.
  • Dr. Sadelain has intellectual property interests in technology licensed by Memorial Sloan Kettering (MSK) to Minerva.

PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune®-Based Anti-Cancer Product

Retrieved on: 
Wednesday, April 29, 2020
RTT, Branches of biology, Medicine, MUC1, Infectious causes of cancer, Papillomavirus, Mucin, Cancer, Human papillomavirus infection

PDS0103 combines Versamune with novel highly immunogenic agonist epitopes of the mucin-1 (MUC1) oncogenic C-terminal region, designed and developed by the LTIB.

Key Points: 
  • PDS0103 combines Versamune with novel highly immunogenic agonist epitopes of the mucin-1 (MUC1) oncogenic C-terminal region, designed and developed by the LTIB.
  • PDS0103 is targeting ovarian, breast, colorectal and lung cancers where over-expression of MUC1 is associated with a high degree of unmet need.
  • PDS0103 monotherapy has demonstrated encouraging results in ongoing preclinical studies, commented Dr. Bedu-Addo, Chief Executive Officer of PDS Biotechnology.
  • In partnership with the National Cancer Institute (NCI), PDS Biotech is advancing a combination of PDS0101, M7824 and NHS-IL12 to a Phase 2 study in advanced HPV-associated cancers.

Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1

Retrieved on: 
Wednesday, January 15, 2020
Research, Technology, FDA, Other Technology, Clinical trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, MUC1, Branches of biology, Mucin, Biology, Pankomab, CA-125, the CART-TnMUC1-01 Phase 1 Trial, Tmunity Therapeutics

The MUC1 glycoprotein is a transmembrane epithelial mucin normally expressed on the apical surface of most simple glandular epithelial cells.

Key Points: 
  • The MUC1 glycoprotein is a transmembrane epithelial mucin normally expressed on the apical surface of most simple glandular epithelial cells.
  • In tumors that arise from these cells, an alternate form of MUC1 is frequently overexpressed on the cancer cell surface.
  • This clinical trial marks the third program from our portfolio to enter the clinical testing phase since our company was founded in 2015.
  • The primary objective of the trial is to establish safety and the recommended Phase 2 dose of CART-TnMUC1 that can be administered with lymphodepletion.

Minerva Biotechnologies Announces FDA Acceptance of IND Application for huMNC2-CAR44 T cells to Treat Metastatic Breast Cancer

Retrieved on: 
Monday, June 24, 2019
Biotechnology, General Health, Oncology, FDA, Health, Other Health, Medicine, Clinical medicine, Branches of biology, Cancer treatments, Immune system, MUC1, Chimeric antigen receptor T cell, Metastatic breast cancer, Tumor antigen vaccine, Tumor-infiltrating lymphocytes, Biotechnology, General Health, Oncology, FDA, Health, Other Health, Medicine, Clinical medicine, Branches of biology, Cancer treatments, Immune system, MUC1, Chimeric antigen receptor T cell, Metastatic breast cancer, Tumor antigen vaccine, Tumor-infiltrating lymphocytes

huMNC2-CAR44 targets MUC1* (muk one star), a cleaved form of MUC1 present on over 75% of solid tumor cancer cells.

Key Points: 
  • huMNC2-CAR44 targets MUC1* (muk one star), a cleaved form of MUC1 present on over 75% of solid tumor cancer cells.
  • Minerva intends to commence clinical trials in breast cancer before the end of 2019.
  • We are delighted that we will soon be able to begin human clinical trials for metastatic breast cancer, said Minerva CEO Dr. Cynthia Bamdad.
  • Minervas chimeric antigen receptor (CAR) technology genetically engineers the patients own immune cells to recognize and kill specific types of cancer cells.

Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 15, 2019
Health, Oncology, Pharmaceutical, Branches of biology, Glycoproteins, Medical specialties, Medicine, MUC1, Drug pipeline, Mucin, Pipeline, Antibody, Monoclonal antibodies, Pankomab

The "Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-Mucin 1 (MUC1) Antibody development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Pipeline Products covered across the following Developmental Stages:
    Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.